Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel by Belderbos, B.P.S.I. (Bodine) et al.
Oncotarget106468www.impactjournals.com/oncotarget
INTRODUCTION
With the introduction of novel agents, treatment 
options for metastatic castration-resistant prostate cancer 
(mCRPC) have notably evolved in the past few years. 
Since level one evidence supporting an optimal treatment 
sequence in mCRPC is lacking, the choice of treatment 
by the clinician has become increasingly challenging. 
Treatment decisions are generally made on the basis of 
clinical symptoms, comorbidities, expected side-effects 
and preferences by the patient and the treating physician. 
Risk classification and prognosis assessment remain 
critical before the start of a new therapy. Therefore, 
it is important to identify biomarkers, predictive and 
prognostic factors for clinical outcome, in order to 
simplify treatment choice and timing. Such factors may 
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ABSTRACT
Background: Treatment selection for men with metastatic castration-resistant 
prostate cancer (mCRPC) has become increasingly challenging with the introduction 
of novel therapies at earlier disease stages. The purpose of this study was to identify 
prognostic factors for overall survival (OS) and PSA response in patients with mCRPC 
treated with cabazitaxel.
Results: 224 mCRPC patients were included in the current analysis. In 
multivariable analysis, WHO performance status, baseline hemoglobin, alkaline 
phosphatase and albumin were all significantly associated with OS. Hemoglobin and 
alkaline phosphatase were significantly associated with PSA response. 
Conclusions: This study identified prognostic factors for OS and PSA response of 
men with mCRPC treated with cabazitaxel. In an increasingly complicated treatment 
landscape with several treatment options available our findings might serve to 
estimate the chance of survival of men qualifying for treatment with second-line 
chemotherapy in daily practice. Furthermore, these data can be used to risk-stratify 
patients in clinical trials.
Methods: We performed a post-hoc analysis of a randomized phase II trial of 
mCRPC patients treated with cabazitaxel. Cox and logistic regression models were 
used to investigate the influence of clinical and biochemical variables on OS and PSA 
response. Nomograms were developed to estimate the chance of PSA response and OS.
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serve to predict individual prognosis at the start of therapy 
and to classify patients in different risk-groups, which can 
also be used for stratification in clinical trials.
Prognostic models and nomograms for mCRPC 
patients receiving first-line chemotherapy have been 
developed based on large phase III trials [1–3], including 
parameters such as performance status, time since last 
docetaxel use, the presence of measurable disease, the 
presence of visceral disease, the presence of pain, duration 
of hormonal treatment, hemoglobin (Hb), prostate specific 
antigen (PSA) and alkaline phosphatase (AP). For second-
line chemotherapy with cabazitaxel, prognostic factors 
were identified based on the TROPIC trial [4, 5]. However, 
these findings have not been investigated in other datasets 
of men treated with cabazitaxel. In the current study, we 
aimed to identify prognostic factors for men with mCRPC 
receiving cabazitaxel. For this purpose, we used data from 
a multicenter randomized phase II trial [6].
RESULTS
Patient characteristics
Baseline characteristics were available for 224 
patients and are shown in Table 1. The characteristics were 
similar to other studies of men treated with second-line 
chemotherapy [5]. 
OS
Median OS of patients in this dataset was 13.3 
months (IQR 7.0–22.3). Results of the univariable and 
multivariable analyses for OS are shown in Table 2. Time 
since last chemotherapy, neutropenia grade 3/4, PSA and 
LDH were significantly associated with OS in univariable 
analysis, but not in multivariable analysis. In multivariable 
analysis, four parameters remained significantly associated 
with OS; WHO performance status (HR 1.49, 95% CI 
1.04–2.13, p = 0.028), Hb (HR 0.73, 95% CI 0.61–0.87, 
p = 0.001), AP (HR 1.50, 95% CI 1.18–1.91, p = 0.001) 
and Alb (HR 0.92, 95% CI 0.89–0.95, p < 0.001). Of 
note, dNLR (p = 0.45) was not associated with OS in 
univariable analysis. 
Figure 1 presents a nomogram that is based on the 
multivariable model for OS. This nomogram can be used 
to predict the individual survival probability at 12 and 
24 months. For example, a patient with a performance 
score of 1, an Hb level of 7.0 mmol/L, albumin level of 
40 g/L and AP of 90 U/L (log_AP = 4,5) has a 12 month 
survival probability of approximately 60% and a 24 month 
survival probability of approximately 20%. 
PSA response
Univariable analysis showed significant associations 
between PSA response and WHO performance status, 
Hb, AP and LDH. In the multivariable model Hb and 
AP remained significantly associated with PSA response 
and were taken into the final model (Table 3).  Higher 
hemoglobin level before treatment (OR 1.48, 95% CI 
1.05–2.07, p = 0.024), and a lower AP level at the start of 
treatment (OR 0.61, 95% CI 0.39–0.96, p = 0.034) resulted 
in a higher chance of PSA response. Figure 2 displays a 
nomogram to calculate the chance of PSA response for an 
individual patient treated with cabazitaxel based on our 
multivariable model.
DISCUSSION 
In this post-hoc analysis of a large phase II trial of 
patients with mCRPC treated with cabazitaxel, we found 
that WHO performance status, baseline Hb, AP and albumin 
were all significantly associated with OS. In addition, 
Hb and AP were identified as parameters to predict the 
probability of PSA response in mCRPC patients receiving 
second-line chemotherapy. To our knowledge, we are the 
first to report prognostic factors and a nomogram for OS and 
PSA response in men with mCRPC treated with cabazitaxel 
outside of the TROPIC registration trial [5]. Treatment 
selection of men with metastatic prostate cancer has become 
increasingly challenging with the introduction of novel 
therapies at earlier disease stages. In this changing treatment 
paradigm, predictors and prognostic factors of treatment 
response and outcome are still lacking. The current study 
shows that readily available, cheap and easy to use clinical 
parameters are of prognostic value for estimating the chance 
of PSA response and OS using the presented nomograms 
(Figures 1 and 2). These individual probabilities of survival 
and response might help the physician to decide when to 
initiate treatment in daily clinical practice. As an illustration, 
if the identified prognostic factors follow a trend towards 
an unfavourable condition, it may help the physician to 
avoid missing the window of opportunity for cabazitaxel 
treatment and initiate therapy before the patients’ condition 
is declining.
Several distinct predictors of OS and PSA response 
(e.g. albumin) were identified as compared to the 
models constructed from the TROPIC dataset [5, 7]. The 
difference between the identified variables in the final 
model from Halabi et al. and our cohort may be due to 
a different population, different primary trial design and 
different model assumptions. The strength of our model 
is that it is based only on men treated with cabazitaxel. 
In contrast, the Halabi nomogram has been constructed 
based on the TROPIC trial and validated on the SPARC 
trial, including also men treated with mitoxantrone and 
satraplatin which are not used in the current treatment 
armamentarium [5]. Therefore, our study might represent 
a more contemporary real-world patient population. 
This study is limited by its post-hoc design. As a result, 
radiographic variables such as the presence of visceral 
disease were not collected in the primary trial. 
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Table 1: Patients characteristics
Characteristic Value No. (%)
All 224 (100)
Age, mean ± SD 68.8 ± 7.2
WHO 
   0 92 (41)
   1 130 (58)
   Missing 2 (1)
Type castration 
   Surgical 30 (13)
   LHRH-analogue 194 (87)
No. prior therapies 
   1  204 (91)
   ≥2 20 (9)
Months since last chemotherapy
   ≤6 months 102 (46)
   ˃6 months 122 (54)
Baseline laboratory results Median (IQR)
   Hb (mmol/L) 7.7 (6.8–8.2)
   Albumin (g/L) 39.0 (36.0–43.0)
   AP (U/L) 130.0 (86.0–262.0)
   LDH (U/L) 271.0 (210.0–392.0)
   ANC (109/L) 5.9 (4.4–7.6)
   PSA (g/L) 154.1 (59–388.3)
   dNLR 2.7 (1.8–3.9)
Abbreviations: WHO = world health organization, Hb = hemoglobin, AP = Alkaline Phosphatase, LDH = lactate 
dehydrogenase, ANC = absolute neutrophil count, PSA = prostate specific antigen, dNLR = derived Neutrophil-
Lymphocyte ratio.
Table 2: Univariable and multivariable model for OS 
Variable Univariable HR(95% CI) P-value
Multivariable HR
(95% CI) P-value
WHO PS 1.57 (1.16–2.13)   0.004 1.49 (1.04–2.13) 0.028 (1 vs 0)
Time since last  
therapy (>6 mths) 0.59 (0.44–0.79)  <0.001
Neutropenia  
(Gr.3/4)
0.67 (0.50–0.90)   0.007  
Hb (mmol/L) 0.57 (0.49–0.67)  <0.001 0.73 (0.61–0.87)   0.001
PSA (log, g/L) 1.12 (1.01–1.26)   0.040
AP (log, U/L) 1.83 (1.49–2.25)   <0.001 1.50 (1.18–1.19)   0.001
LDH (log, U/L) 2.37 (1.73–3.25)   <0.001
Albumin (g/L) 0.91 (0.89–0.94)   <0.001 0.92 (0.89–0.95)   <0.001
Univariable N = 206–224 (because of missing values the number of included patients can differ per variable) Multivariable 
N = 200.
Abbreviations: WHO PS = world health organization performance status, Hb = hemoglobin, PSA = prostate specific antigen, 
AP = alkaline phosphatase, LDH = lactate dehydrogenase, log = log transformed variables when data were not normally 
distributed.
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dNLR, a parameter to determine the inflammatory 
response rate of the host, has been reported and validated 
as a prognostic factor for OS and response in mCRPC 
patients treated with docetaxel, cabazitaxel and abiraterone 
[7–10]. In addition, a high dNLR was associated with poor 
OS in other tumor types [11]. However, in our analyses 
no significant association between dNLR and OS, nor 
between dNLR and PSA response was found. Furthermore, 
in a post-hoc analysis of the TROPIC trial neutropenia 
during treatment with cabazitaxel has shown a significant 
relation with OS of men with mCRPC [12]. Although we 
had comparable treatment groups, no association between 
the occurrence of grade 3–4 neutropenia and OS or PSA 
response was found.
In conclusion, this study identified clinical and 
biochemical variables associated with OS and PSA 
response of patients with mCRPC treated with cabazitaxel. 
In an increasingly complicated treatment landscape 
with several treatment options available including 
chemotherapy and novel AR-targeted agents, our findings 
have prognostic value for treatment response and 
survival of men qualifying for treatment with second-line 
chemotherapy in daily practice. Furthermore, these data 
can be used to risk-stratify patients in future clinical trials.
PATIENTS AND METHODS
Patients
We performed a post-hoc analysis of a randomized 
phase II trial (CABARESC, NTR2991). The CABARESC 
trial was designed to investigate the influence of 
budesonide (9 mg daily) on cabazitaxel pharmacokinetics 
and cabazitaxel-induced diarrhea and was reported 
elsewhere [6]. Between December 2011 and October 
2015, a total of 246 mCRPC patients were included in 
the study. The study was conducted in 22 Dutch hospitals 
and was approved by the ethics committee of the Erasmus 
MC (MEC 11-324) and all local institutional review 
boards. Written informed consent was obtained from all 
participants.
Full study details are described in the original paper 
[6]. Briefly, patients were eligible if they had metastatic 
castration-resistant adenocarcinoma of the prostate with 
Figure 1: Nomogram for OS. Prognostic nomogram predicting overall survival probability. For each variable, starting with WHO 
performance score on the second axis, draw a vertical line up to the ‘Points’ axis (top line) to identify the number of prognostic points the 
patient receives for the value of this variable. Calculate the ‘Total Points’ by adding up the prognostic points for each variable. Determine 
the 12 month or 24 month overall survival by drawing a vertical line from the ‘Total Points’ axis down to the axis indicating the survival 
probabilty.  WHO PS = world health organization performance status, Hb = hemoglobin, AP = alkaline phosphatase, log = log transformed 
variables when data were not normally distributed.
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disease progression during or after docetaxel therapy, 
defined as two consecutive rises in PSA (taken ≥1 week 
apart) or according to RECIST criteria. Full inclusion 
criteria are shown in Supplementary materials. In 
this study, no significant impact of budesonide on the 
pharmacokinetics of cabazitaxel and cabazitaxel-induced 
diarrhea was found. We have previously shown that there 
was no influence of prior treatment with abiraterone 
acetate or enzalutamide on OS and PSA response of men 
treated with cabazitaxel [13]. Patients who were deemed 
inevaluable in the original CABARESC trial (N = 19) 
(Supplementary Table 1) and patients with missing or 
inadequate PSA values were considered ineligible for the 
current analysis (N = 3), leaving 224 patients evaluable for 
the current analysis.
Biomarker panel 
From all evaluable patients, laboratory and clinical 
factors collected at baseline and during treatment were 
Figure 2: Nomogram for PSA response. Prognostic nomogram predicting PSA response. For both variables, Hb and AP_log, draw a 
vertical line from the absolute value of this variable up to the ‘Points’ axis (top line) to identify the number of prognostic points the patient 
receives for these variables. Calculate the ‘Total Points’ by adding up the prognostic points for both variables. Determine the probability of 
PSA response by drawing a vertival line form the ‘Total Points’ axis down to the axis of the probability of PSA response. Hb = hemoglobin, 
AP = alkaline phosphatase, log = log transformed variables when data were not normally distributed.
Table 3: Univariable and multivariable model for PSA response 
Variable UnivariableOR (95% CI) P-value
Multivariable
OR (95% CI) P-value
WHO PS 0.48 (0.27–0.84) 0.011
 (1 vs 0)
Hb (mmol/L) 1.67 (1.22–2.29) 0.002 1.48 (1.05–2.07) 0.024
AP (log, U/L) 0.50 (0.33–0.77) 0.002 0.61 (0.39–0.96) 0.034
LDH (log, U/L) 0.49 (0.27–0.88) 0.016
Univariable N = 217–224 (because of missing values the number of included patients can differ per variable) 
Multivariable N = 215.
Abbreviations: WHO PS = world health organization performance status, Hb = hemoglobin, AP = alkaline phosphatase, 
LDH = lactate dehydrogenase, log = log transformed variables when data were not normally distributed.
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available. The biochemical parameters were collected at 
baseline included: PSA, lactate dehydrogenase (LDH), 
AP, albumin (Alb), Hb, derived neutrophil-lymphocyte 
ratio (dNLR), WHO performance status (0 vs 1), age, type 
of castration (GnRH analogues vs. surgical castration) 
and time since last chemotherapy cycle (>6 months vs 
≤6 months). The dNLR was computed by the absolute 
neutrophil count (ANC) divided by the absolute white 
blood cell count (WBC) minus the ANC, (ANC/ (WBC-
ANC)). The occurrence of ≥grade 3 neutropenia during 
treatment was collected. Log transformation was applied 
to variables with a non-normal distribution.
Primary objective and definitions
The objective of the current analysis was to identify 
prognostic factors associated with OS and PSA response in 
mCRPC patients treated with cabazitaxel. OS was defined 
by time from randomization to death from any cause. 
Patients still alive at the end of the study were censored. 
Prostate Cancer Working Group 2 (PCWG2) criteria were 
used to define PSA response as a ≥50% decline from 
baseline measured twice 3 to 4 weeks apart [14]. 
Statistical analysis
Descriptive statistics were used to summarize 
patients’ characteristics. Univariable and multivariable 
Cox regression analyses were used to investigate the 
influence of laboratory and clinical parameters on OS. 
Univariable and multivariable logistic regression analysis 
were used with PSA response (≥50%) as the dependent 
variable and baseline parameters were included as 
covariates. Factors with a p < 0.10 in univariable 
analysis were entered into the multivariable analysis. The 
multivariable model was constructed using backward 
selection at the 5% level. Data were analyzed using 
STATA® version 14 (Stata-Corp LP TX, USA).
Based on the multivariable model for OS and PSA 
response we have generated a nomogram for OS and PSA 
response. Software program ‘R’ was used to generate both 
nomograms.
Abbrevations
ANC, absolute neutrophil count; AP, alkaline 
phosphatase; Alb, albumin; CI, confindence interval; 
dNLR, derived neutrophil-lymphocyte ratio; GnRH, 
Gonadotropin releasing hormone; Hb, hemoglobin; HR, 
hazard ratio; IQR, inter quartile range; LDH, lactate 
dehydrogenase; mCRPC, metastatic castration resistant 
prostate cancer; OR, odds ratio; OS, Overall survival; 
PCWG2, prostate cancer working group 2; PSA, prostate 
specific antigen; RECIST, response evaluation criteria 
in solid tumor; WBC, white blood cell count; WHO PS, 
world health organization performance status.
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